doxylamine has been researched along with Emesis in 39 studies
Doxylamine: Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in PARKINSONISM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report information about an unpublished 1970s study ("8-way" Bendectin Study) that aimed to evaluate the relative therapeutic efficacy of doxylamine, pyridoxine, and dicyclomine in the management of nausea and vomiting during pregnancy." | 9.24 | 8-Way Randomized Controlled Trial of Doxylamine, Pyridoxine and Dicyclomine for Nausea and Vomiting during Pregnancy: Restoration of Unpublished Information. ( Persaud, N; Zhang, R, 2017) |
| "Doxylamine succinate-pyridoxine hydrochloride delayed release combination is safe and well tolerated by pregnant women when used in the recommended dose of up to 4 tablets daily in treating nausea and vomiting of pregnancy." | 9.20 | Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. ( Caritis, SN; Clark, S; Hankins, GD; Koren, G; Matok, I; Mattison, DR; Miodovnik, M; Umans, JG, 2015) |
| "Our investigation showed ondansetron to be superior to the combination of pyridoxine and doxylamine in the treatment of nausea and emesis in pregnancy." | 9.19 | Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial. ( Capp, SM; Carstairs, SD; Oliveira, LG; Riffenburgh, RH; You, WB, 2014) |
| " The authors' objective is to identify the determinants of adherence to delayed-release doxylamine-pyridoxine (Diclectin) in patients with nausea and vomiting of pregnancy (NVP)." | 9.16 | Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy. ( Caritis, S; Chiossi, G; Clark, S; Costantine, MM; Hankins, GD; Koren, G; Matok, I; Miodovnik, M; Umans, JG, 2012) |
| "To evaluate the effectiveness of Diclectin (doxylamine succinate 10 mg-pyridoxine hydrochloride 10 mg, delayed-release preparation) as compared with placebo for nausea and vomiting of pregnancy." | 9.14 | Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. ( Caritis, SN; Clark, S; Hankins, GD; Koren, G; Mattison, DR; Miodovnik, M; Umans, JG, 2010) |
| "Diclectin (pyridoxine 10 mg and doxylamine 10 mg) has traditionally been used to treat nausea and vomiting of pregnancy (NVP); however, this drug is unavailable in many countries." | 7.79 | Evaluation of the efficacy and safety of bi-daily combination therapy with pyridoxine and doxylamine for nausea and vomiting of pregnancy. ( Ashkenazi-Hoffnung, L; Klinger, G; Merlob, P; Stahl, B, 2013) |
| "A delayed-release combination of doxylamine-pyridoxine (D-P) (Diclectin) is the only approved antiemetic medication for use in pregnancy in Canada." | 7.71 | The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy. ( Atanackovic, G; Koren, G; Moretti, ME; Navioz, Y, 2001) |
| "An effective and safe treatment for nausea and vomiting of pregnancy (NVP) is lacking." | 7.30 | Acupuncture and Doxylamine-Pyridoxine for Nausea and Vomiting in Pregnancy : A Randomized, Controlled, 2 ( An, CM; Cao, YJ; Chen, XY; Cong, J; Cui, YM; Feng, YH; Gao, JS; Hu, YH; Li, J; Li, L; Liu, JP; Liu, L; Liu, YX; Liu, ZL; Liu, ZS; Lu, ZL; Ma, HL; Mol, BWJ; Ng, EHY; Painter, RC; Qi, X; Qin, HC; Wang, CC; Wang, Y; Wang, YX; Wu, Q; Wu, XK; Yan, Y; Yang, XM; Yu, L; Zhang, B; Zhou, LL, 2023) |
| "We report information about an unpublished 1970s study ("8-way" Bendectin Study) that aimed to evaluate the relative therapeutic efficacy of doxylamine, pyridoxine, and dicyclomine in the management of nausea and vomiting during pregnancy." | 5.24 | 8-Way Randomized Controlled Trial of Doxylamine, Pyridoxine and Dicyclomine for Nausea and Vomiting during Pregnancy: Restoration of Unpublished Information. ( Persaud, N; Zhang, R, 2017) |
| "Doxylamine succinate-pyridoxine hydrochloride delayed release combination is safe and well tolerated by pregnant women when used in the recommended dose of up to 4 tablets daily in treating nausea and vomiting of pregnancy." | 5.20 | Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. ( Caritis, SN; Clark, S; Hankins, GD; Koren, G; Matok, I; Mattison, DR; Miodovnik, M; Umans, JG, 2015) |
| "Our investigation showed ondansetron to be superior to the combination of pyridoxine and doxylamine in the treatment of nausea and emesis in pregnancy." | 5.19 | Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial. ( Capp, SM; Carstairs, SD; Oliveira, LG; Riffenburgh, RH; You, WB, 2014) |
| " The authors' objective is to identify the determinants of adherence to delayed-release doxylamine-pyridoxine (Diclectin) in patients with nausea and vomiting of pregnancy (NVP)." | 5.16 | Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy. ( Caritis, S; Chiossi, G; Clark, S; Costantine, MM; Hankins, GD; Koren, G; Matok, I; Miodovnik, M; Umans, JG, 2012) |
| "To evaluate the effectiveness of Diclectin (doxylamine succinate 10 mg-pyridoxine hydrochloride 10 mg, delayed-release preparation) as compared with placebo for nausea and vomiting of pregnancy." | 5.14 | Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. ( Caritis, SN; Clark, S; Hankins, GD; Koren, G; Mattison, DR; Miodovnik, M; Umans, JG, 2010) |
| " We used as a motivating example the possible teratogenic risks of antiemetic agents in pregnancy since a large observational study recently showed that first-trimester exposure to doxylamine-pyridoxine was associated with significantly increased risk of congenital malformations as a whole, as well as central nervous system defects, and previous observational studies did not show such associations." | 5.12 | Misleading meta-analyses of observational studies may generate unjustified alarms: The case of medications for nausea and vomiting in pregnancy. ( Biffi, A; Cetin, I; Corrao, G; Filippelli, A; Locatelli, A; Rea, F, 2021) |
| "A double-blind comparison was undertaken between Debendox with 10mg of extra pyridoxine and placebo with 10mg of pyridoxine, in 56 women suffering from nausea and/or vomiting during the first 10 weeks of pregnancy." | 5.04 | Treatment of pregnancy sickness. ( Wheatley, D, 1977) |
| "For mild symptoms of nausea and emesis of pregnancy, ginger, pyridoxine, antihistamines, and metoclopramide were associated with greater benefit than placebo." | 4.93 | Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review. ( Beyer, F; Bradley, J; Bryant, A; McParlin, C; Moloney, E; Muirhead, CR; Nelson-Piercy, C; Newbury-Birch, D; Norman, J; O'Donnell, A; Robson, SC; Shaw, C; Simpson, E; Swallow, B; Vale, L; Yates, L, 2016) |
| "Using the Quebec Pregnancy Cohort (1998-2015), first-trimester doxylamine-pyridoxine, metoclopramide, and ondansetron exposures were assessed for their association with MCM." | 3.91 | New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy. ( Bérard, A; Bernatsky, S; Gorgui, J; Sheehy, O; Soares de Moura, C; Zhao, JP, 2019) |
| "Diclectin (pyridoxine 10 mg and doxylamine 10 mg) has traditionally been used to treat nausea and vomiting of pregnancy (NVP); however, this drug is unavailable in many countries." | 3.79 | Evaluation of the efficacy and safety of bi-daily combination therapy with pyridoxine and doxylamine for nausea and vomiting of pregnancy. ( Ashkenazi-Hoffnung, L; Klinger, G; Merlob, P; Stahl, B, 2013) |
| "Diclectin, composed of 10 mg doxylamine succinate (DOX) and 10 mg pyridoxine hydrochloride, is the drug combination of choice for the management of nausea and vomiting during pregnancy in Canada." | 3.77 | Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin). ( Garcia-Bournissen, F; Gill, SK; Koren, G, 2011) |
| "Women who called the Motherisk NVP helpline, and were taking only Diclectin (vitamin B6 10 mg and doxylamine 10 mg), were enrolled in the study and assessed for the severity of nausea and vomiting of pregnancy (NVP) with the Motherisk-PUQE (pregnancy-unique quantification of emesis and nausea) scoring system." | 3.72 | Diclectin therapy for nausea and vomiting of pregnancy: effects of optimal dosing. ( Boskovic, R; Einarson, A; Koren, G; Maltepe, C; Wolpin, J, 2003) |
| "A delayed-release combination of doxylamine-pyridoxine (D-P) (Diclectin) is the only approved antiemetic medication for use in pregnancy in Canada." | 3.71 | The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy. ( Atanackovic, G; Koren, G; Moretti, ME; Navioz, Y, 2001) |
| "I have a 30-year-old pregnant patient who is asthmatic and is taking prednisone." | 3.70 | Managing women with nausea and vomiting of pregnancy. Canadian consensus. ( , 2000) |
| "An effective and safe treatment for nausea and vomiting of pregnancy (NVP) is lacking." | 3.30 | Acupuncture and Doxylamine-Pyridoxine for Nausea and Vomiting in Pregnancy : A Randomized, Controlled, 2 ( An, CM; Cao, YJ; Chen, XY; Cong, J; Cui, YM; Feng, YH; Gao, JS; Hu, YH; Li, J; Li, L; Liu, JP; Liu, L; Liu, YX; Liu, ZL; Liu, ZS; Lu, ZL; Ma, HL; Mol, BWJ; Ng, EHY; Painter, RC; Qi, X; Qin, HC; Wang, CC; Wang, Y; Wang, YX; Wu, Q; Wu, XK; Yan, Y; Yang, XM; Yu, L; Zhang, B; Zhou, LL, 2023) |
| "Nausea and vomiting are common in early pregnancy." | 2.50 | The pharmacologic management of nausea and vomiting of pregnancy. ( Briggs, GG; Niebyl, JR, 2014) |
| "Phenothiazines should be reserved for treating persistent vomiting that threatens the maternal nutritional status." | 2.37 | Safety and efficacy of antiemetics used to treat nausea and vomiting in pregnancy. ( Leathem, AM, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (30.77) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (28.21) | 29.6817 |
| 2010's | 13 (33.33) | 24.3611 |
| 2020's | 3 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Saz-Leal, P | 1 |
| Zamorano-Domínguez, L | 1 |
| Frías, J | 1 |
| Guerra, P | 1 |
| Saura-Valls, M | 1 |
| Roca-Juanes, R | 1 |
| Nebot-Troyano, J | 1 |
| García-Aguilar, E | 1 |
| Vilchez, T | 1 |
| Urso, K | 1 |
| Wu, XK | 1 |
| Gao, JS | 1 |
| Ma, HL | 1 |
| Wang, Y | 1 |
| Zhang, B | 1 |
| Liu, ZL | 1 |
| Li, J | 1 |
| Cong, J | 1 |
| Qin, HC | 1 |
| Yang, XM | 1 |
| Wu, Q | 1 |
| Chen, XY | 1 |
| Lu, ZL | 1 |
| Feng, YH | 1 |
| Qi, X | 1 |
| Wang, YX | 1 |
| Yu, L | 1 |
| Cui, YM | 1 |
| An, CM | 1 |
| Zhou, LL | 1 |
| Hu, YH | 1 |
| Li, L | 1 |
| Cao, YJ | 1 |
| Yan, Y | 1 |
| Liu, L | 1 |
| Liu, YX | 1 |
| Liu, ZS | 1 |
| Painter, RC | 1 |
| Ng, EHY | 1 |
| Liu, JP | 1 |
| Mol, BWJ | 1 |
| Wang, CC | 1 |
| Biffi, A | 1 |
| Rea, F | 1 |
| Locatelli, A | 1 |
| Cetin, I | 1 |
| Filippelli, A | 1 |
| Corrao, G | 1 |
| Bérard, A | 1 |
| Sheehy, O | 1 |
| Gorgui, J | 1 |
| Zhao, JP | 1 |
| Soares de Moura, C | 1 |
| Bernatsky, S | 1 |
| Ashkenazi-Hoffnung, L | 1 |
| Merlob, P | 1 |
| Stahl, B | 1 |
| Klinger, G | 1 |
| Niebyl, JR | 1 |
| Briggs, GG | 1 |
| Madjunkova, S | 1 |
| Maltepe, C | 3 |
| Koren, G | 10 |
| Oliveira, LG | 1 |
| Capp, SM | 1 |
| You, WB | 1 |
| Riffenburgh, RH | 1 |
| Carstairs, SD | 1 |
| Clark, S | 3 |
| Hankins, GD | 3 |
| Caritis, SN | 2 |
| Umans, JG | 3 |
| Miodovnik, M | 3 |
| Mattison, DR | 2 |
| Matok, I | 2 |
| McParlin, C | 1 |
| O'Donnell, A | 1 |
| Robson, SC | 1 |
| Beyer, F | 1 |
| Moloney, E | 1 |
| Bryant, A | 1 |
| Bradley, J | 1 |
| Muirhead, CR | 1 |
| Nelson-Piercy, C | 1 |
| Newbury-Birch, D | 1 |
| Norman, J | 1 |
| Shaw, C | 1 |
| Simpson, E | 1 |
| Swallow, B | 1 |
| Yates, L | 1 |
| Vale, L | 1 |
| Zhang, R | 1 |
| Persaud, N | 1 |
| Nulman, I | 1 |
| Rovet, J | 1 |
| Barrera, M | 1 |
| Knittel-Keren, D | 1 |
| Feldman, BM | 1 |
| Gill, SK | 1 |
| Garcia-Bournissen, F | 2 |
| Costantine, MM | 1 |
| Chiossi, G | 1 |
| Caritis, S | 1 |
| Brent, R | 2 |
| Kutcher, JS | 1 |
| Engle, A | 1 |
| Firth, J | 1 |
| Lamm, SH | 1 |
| Quinla, JD | 1 |
| Hill, DA | 1 |
| TOWNE, JE | 1 |
| GEIGER, CJ | 1 |
| FAHRENBACH, DM | 1 |
| HEALEY, FJ | 1 |
| Boskovic, R | 1 |
| Einarson, A | 1 |
| Wolpin, J | 1 |
| Staroselsky, A | 1 |
| Huff, PS | 1 |
| David, TJ | 1 |
| Mitchell, AA | 1 |
| Rosenberg, L | 1 |
| Shapiro, S | 1 |
| Slone, D | 1 |
| Harron, DW | 1 |
| Griffiths, K | 1 |
| Shanks, RG | 1 |
| Mazzotta, P | 1 |
| Navioz, Y | 2 |
| Magee, LA | 1 |
| Atanackovic, G | 1 |
| Moretti, ME | 1 |
| Strong, TH | 1 |
| Wheatley, D | 1 |
| Check, WA | 1 |
| Shiono, PH | 1 |
| Klebanoff, MA | 1 |
| Leathem, AM | 1 |
| Walters, WA | 1 |
| Elbourne, D | 1 |
| Mutch, L | 1 |
| Dauncey, M | 1 |
| Campbell, H | 1 |
| Samphier, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022[NCT06055192] | 200 participants (Anticipated) | Observational | 2023-09-30 | Not yet recruiting | |||
| Is Zofran Superior to Pyridoxine at Reducing Nausea and Vomiting in Pregnancy[NCT01668069] | 36 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| A Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Of The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy[NCT00614445] | Phase 3 | 280 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Is the Application of Scopolamine Patch With or Without Intra-operative Acupressure Point P6 Stimulation More Effective Than Intra-operative Acupressure Point P6 Stimulation Alone?[NCT02960113] | Phase 4 | 240 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The objective of this double-blind, randomized, placebo-controlled study was to assess the efficacy, safety, and tolerability of oral Diclectin® in the treatment of nausea and vomiting of pregnancy (NVP) as measured by the Pregnancy Unique-Quantification of Emesis (PUQE) overall score of symptoms from baseline (Day 1) to end of study visit (Day 15). The PUQE score measured hours of nausea, number of times vomiting, and number of times retching for a TOTAL overall score of symptoms on a scale rated from 3 (no symptoms) to 15 (most severe). (NCT00614445)
Timeframe: Baseline (Day 1) to End of Study Visit Day 15 (± 1 day)
| Intervention | PUQE Score (Mean) |
|---|---|
| Diclectin® | -4.8 |
| Placebo | -3.9 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after eversion of the uterus. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: After eversion of the uterus until replacement of the uterus
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 1.28 |
| Acupressure Point P6 | 1.09 |
| Scopolamine Patch + Acupressure Point P6 | 1.40 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after replacement of the uterus. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: After replacement of the uterus and to the next 15 minutes
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 2.19 |
| Acupressure Point P6 | 2.19 |
| Scopolamine Patch + Acupressure Point P6 | 2.51 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after the administration of the regional anesthesia medications. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: From administration of anaesthesia until eversion of uterus
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 2.71 |
| Acupressure Point P6 | 2.57 |
| Scopolamine Patch + Acupressure Point P6 | 2.84 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) upon arrival to the post-operative recovery room. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: 15 minutes after replacement of the uterus to arrival at post-anaesthesia care unit
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 0.18 |
| Acupressure Point P6 | 0.25 |
| Scopolamine Patch + Acupressure Point P6 | 0.23 |
The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea at any point during the surgical procedure in each group. (NCT02960113)
Timeframe: Throughout the entire surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 40 |
| Acupressure Point P6 | 39 |
| Scopolamine Patch + Acupressure Point P6 | 46 |
The investigators will perform objective assessments of whether or not the patients have vomited during the procedure. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: Throughout the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 24 |
| Acupressure Point P6 | 25 |
| Scopolamine Patch + Acupressure Point P6 | 31 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After eversion of to replacement of the uterus
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 8 |
| Acupressure Point P6 | 6 |
| Scopolamine Patch + Acupressure Point P6 | 9 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After replacement of the uterus and for next 15 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 10 |
| Acupressure Point P6 | 15 |
| Scopolamine Patch + Acupressure Point P6 | 12 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After the administration of the regional anesthesia medications until eversion of the uterus
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 20 |
| Acupressure Point P6 | 15 |
| Scopolamine Patch + Acupressure Point P6 | 20 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: From 15 minutes after replacement of the uterus until arrival at the post-anaesthesia care unit
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 1 |
| Acupressure Point P6 | 1 |
| Scopolamine Patch + Acupressure Point P6 | 4 |
Patients are asked their nausea and vomiting treatment satisfaction (0 = Not Satisfied, 10 = Extremely Satisfied). Patients are also asked their overall satisfaction with the procedure (0 = Not Satisfied, 10 = Extremely Satisfied). (NCT02960113)
Timeframe: Throughout the surgical procedure
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 9.29 |
| Acupressure Point P6 | 8.96 |
| Scopolamine Patch + Acupressure Point P6 | 9.59 |
10 reviews available for doxylamine and Emesis
| Article | Year |
|---|---|
Misleading meta-analyses of observational studies may generate unjustified alarms: The case of medications for nausea and vomiting in pregnancy.
Topics: Abnormalities, Drug-Induced; Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans | 2021 |
Doxylamine/pyridoxine for nausea and vomiting in pregnancy.
Topics: Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans; Nausea; Practice Guidelines | 2019 |
The pharmacologic management of nausea and vomiting of pregnancy.
Topics: Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Histamine H1 Antagonists; Humans; N | 2014 |
The delayed-release combination of doxylamine and pyridoxine (Diclegis®/Diclectin ®) for the treatment of nausea and vomiting of pregnancy.
Topics: Antiemetics; Delayed-Action Preparations; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans | 2014 |
Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review.
Topics: Acupuncture; Adrenal Cortex Hormones; Antiemetics; Doxylamine; Female; Histamine Antagonists; Humans | 2016 |
Nausea and vomiting of pregnancy.
Topics: Acupressure; Antiemetics; Diagnosis, Differential; Doxylamine; Female; Humans; Hyperemesis Gravidaru | 2003 |
Safety of drug therapy for nausea and vomiting of pregnancy.
Topics: Abnormalities, Drug-Induced; Antiemetics; Child; Dicyclomine; Doxylamine; Drug Combinations; Female; | 1980 |
Alternative therapies of morning sickness.
Topics: Acupressure; Antiemetics; Complementary Therapies; Dicyclomine; Doxylamine; Drug Combinations; Femal | 2001 |
Medical, social, and legal implications of treating nausea and vomiting of pregnancy.
Topics: Abnormalities, Drug-Induced; Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans | 2002 |
Safety and efficacy of antiemetics used to treat nausea and vomiting in pregnancy.
Topics: Antiemetics; Antipsychotic Agents; Dicyclomine; Diphenhydramine; Doxylamine; Drug Combinations; Fema | 1986 |
7 trials available for doxylamine and Emesis
| Article | Year |
|---|---|
Acupuncture and Doxylamine-Pyridoxine for Nausea and Vomiting in Pregnancy : A Randomized, Controlled, 2
Topics: Acupuncture Therapy; Antiemetics; Child; Doxylamine; Female; Humans; Nausea; Pregnancy; Pregnancy Co | 2023 |
Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial.
Topics: Adult; Antiemetics; Double-Blind Method; Doxylamine; Drug Therapy, Combination; Female; Follow-Up St | 2014 |
Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial.
Topics: Adult; Antiemetics; Delayed-Action Preparations; Dicyclomine; Double-Blind Method; Doxylamine; Drug | 2015 |
8-Way Randomized Controlled Trial of Doxylamine, Pyridoxine and Dicyclomine for Nausea and Vomiting during Pregnancy: Restoration of Unpublished Information.
Topics: Cooperative Behavior; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans; Nausea; Physicians | 2017 |
Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial.
Topics: Adult; Delayed-Action Preparations; Dicyclomine; Dose-Response Relationship, Drug; Double-Blind Meth | 2010 |
Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial.
Topics: Adult; Delayed-Action Preparations; Dicyclomine; Dose-Response Relationship, Drug; Double-Blind Meth | 2010 |
Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial.
Topics: Adult; Delayed-Action Preparations; Dicyclomine; Dose-Response Relationship, Drug; Double-Blind Meth | 2010 |
Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial.
Topics: Adult; Delayed-Action Preparations; Dicyclomine; Dose-Response Relationship, Drug; Double-Blind Meth | 2010 |
Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy.
Topics: Adult; Antiemetics; Cohort Studies; Delayed-Action Preparations; Dicyclomine; Double-Blind Method; D | 2012 |
Treatment of pregnancy sickness.
Topics: Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dicyclomine; Double-Blind Method; Doxylamine; | 1977 |
22 other studies available for doxylamine and Emesis
| Article | Year |
|---|---|
Bioavailability of Cariban
Topics: Adult; Antiemetics; Biological Availability; Capsules; Delayed-Action Preparations; Doxylamine; Drug | 2023 |
New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cohort Studies; Dicyclomine; Doxylamine; Drug Combi | 2019 |
Evaluation of the efficacy and safety of bi-daily combination therapy with pyridoxine and doxylamine for nausea and vomiting of pregnancy.
Topics: Administration, Oral; Adult; Antiemetics; Case-Control Studies; Dicyclomine; Dose-Response Relations | 2013 |
Diclegis for nausea and vomiting of pregnancy.
Topics: Antiemetics; Delayed-Action Preparations; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans | 2013 |
Long-term neurodevelopment of children exposed to maternal nausea and vomiting of pregnancy and diclectin.
Topics: Adult; Antiemetics; Child; Child Development; Child, Preschool; Cohort Studies; Dicyclomine; Doxylam | 2009 |
Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin).
Topics: Adult; Antiemetics; Biological Availability; Canada; Delayed-Action Preparations; Dicyclomine; Doxyl | 2011 |
Bendectin and birth defects: hopefully, the final chapter.
Topics: Abnormalities, Drug-Induced; Adult; Adverse Drug Reaction Reporting Systems; Animals; Antiemetics; C | 2003 |
Bendectin and birth defects. II: Ecological analyses.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Adverse Drug Reaction Reporting Systems | 2003 |
Nausea and vomiting of pregnancy: treatment with bendectin.
Topics: Dicyclomine; Doxylamine; Drug Combinations; Histamine H1 Antagonists; Muscle Relaxants, Central; Nau | 1958 |
Bendectin in the treatment of nausea and vomiting in pregnancy.
Topics: Dicyclomine; Doxylamine; Drug Combinations; Histamine H1 Antagonists; Muscle Relaxants, Central; Nau | 1959 |
Diclectin therapy for nausea and vomiting of pregnancy: effects of optimal dosing.
Topics: Adult; Antiemetics; Dose-Response Relationship, Drug; Doxylamine; Drug Combinations; Female; Humans; | 2003 |
American Gastroenterological Association institute medical position statement on the use of gastrointestinal medication in pregnancy.
Topics: Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Gastrointestinal Agents; Gastrointe | 2007 |
Debendox does not cause the Poland anomaly.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Antiemetics; Dicyclomine; Doxylamine; Drug Com | 1982 |
Birth defects related to bendectin use in pregnancy. I. Oral clefts and cardiac defects.
Topics: Antiemetics; Cleft Lip; Cleft Palate; Dicyclomine; Doxylamine; Drug Combinations; Drug Evaluation; F | 1981 |
Debendox and congenital malformations in Northern Ireland.
Topics: Abnormalities, Drug-Induced; Antiemetics; Cyclohexanecarboxylic Acids; Dicyclomine; Doxylamine; Drug | 1980 |
Managing women with nausea and vomiting of pregnancy. Canadian consensus.
Topics: Adult; Anti-Inflammatory Agents; Antiemetics; Asthma; Diagnosis, Differential; Doxylamine; Drug Ther | 2000 |
Attitudes, management and consequences of nausea and vomiting of pregnancy in the United States and Canada.
Topics: Adult; Antiemetics; Attitude; Attitude of Health Personnel; Canada; Cost of Illness; Dicyclomine; Di | 2000 |
The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy.
Topics: Antiemetics; Doxylamine; Drug Combinations; Female; Humans; Infant, Newborn; Nausea; Pregnancy; Preg | 2001 |
CDC study: no evidence for teratogenicity of Bendectin.
Topics: Abnormalities, Drug-Induced; Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Heart | 1979 |
Bendectin and human congenital malformations.
Topics: Abnormalities, Drug-Induced; Central Nervous System; Dicyclomine; Digestive System Abnormalities; Do | 1989 |
The management of nausea and vomiting during pregnancy.
Topics: Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans; Legislation, Drug; Nausea; | 1987 |
Debendox revisited.
Topics: Abnormalities, Drug-Induced; Antiemetics; Cleft Lip; Cleft Palate; Dicyclomine; Doxylamine; Drug Com | 1985 |